351 related articles for article (PubMed ID: 12901225)
41. Telomeres and telomerase as targets for cancer therapy.
Zimmermann S; Martens UM
Cell Mol Life Sci; 2007 Apr; 64(7-8):906-21. PubMed ID: 17310277
[TBL] [Abstract][Full Text] [Related]
42. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.
Pantic M; Zimmermann S; Waller CF; Martens UM
Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713
[TBL] [Abstract][Full Text] [Related]
43. In vivo regulation of telomerase activity and telomere length.
Hathcock KS; Jeffrey Chiang Y; Hodes RJ
Immunol Rev; 2005 Jun; 205():104-13. PubMed ID: 15882348
[TBL] [Abstract][Full Text] [Related]
44. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
45. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
Goldkorn A; Blackburn EH
Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
[TBL] [Abstract][Full Text] [Related]
46. How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex.
Bianchi A; Shore D
Mol Cell; 2008 Jul; 31(2):153-65. PubMed ID: 18657499
[TBL] [Abstract][Full Text] [Related]
47. How to inhibit telomerase activity for cancer therapy.
Kyo S; Inoue M
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
[TBL] [Abstract][Full Text] [Related]
48. Telomere dysfunction and telomerase activation in cancer--a pathological paradox?
Calcagnile O; Gisselsson D
Cytogenet Genome Res; 2007; 118(2-4):270-6. PubMed ID: 18000380
[TBL] [Abstract][Full Text] [Related]
49. [Telomeres and telomerase as targeted therapies in cancer treatment].
Souiden Y; Bouraoui A; Chaieb K; Mahdouani K
Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741
[TBL] [Abstract][Full Text] [Related]
50. Telomere-based cancer treatment: emerging targeted therapies.
Chen M; McLeskey SW
Clin J Oncol Nurs; 2010 Dec; 14(6):720-6. PubMed ID: 21112850
[TBL] [Abstract][Full Text] [Related]
51. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
[TBL] [Abstract][Full Text] [Related]
52. Correlation of telomerase activity and telomere length to chemosensitivity.
Kiyozuka Y
Methods Mol Med; 2005; 111():97-108. PubMed ID: 15911975
[TBL] [Abstract][Full Text] [Related]
53. Telomerase inhibitors for the treatment of cancer: the current perspective.
Perry PJ; Arnold JR; Jenkins TC
Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
[TBL] [Abstract][Full Text] [Related]
54. Agents that target telomerase and telomeres.
Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
[TBL] [Abstract][Full Text] [Related]
55. Telomerase inhibition, oligonucleotides, and clinical trials.
Corey DR
Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789
[TBL] [Abstract][Full Text] [Related]
56. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
57. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro.
Kelleher C; Kurth I; Lingner J
Mol Cell Biol; 2005 Jan; 25(2):808-18. PubMed ID: 15632080
[TBL] [Abstract][Full Text] [Related]
58. Telomerase: biology and phase I trials.
Kelland LR
Lancet Oncol; 2001 Feb; 2(2):95-102. PubMed ID: 11905801
[TBL] [Abstract][Full Text] [Related]
59. [Telomeres, telomerase and cancer].
Soria JC; Rixe O
Bull Cancer; 1997 Oct; 84(10):963-70. PubMed ID: 9435798
[TBL] [Abstract][Full Text] [Related]
60. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
Cerone MA; Londoño-Vallejo JA; Autexier C
Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
